Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

Pulmonary Hypertension associated with Interstitial Lung Disease Market Outlook and Forecast

Thelansis’s "Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pulmonary Hypertension associated with Interstitial Lung Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pulmonary Hypertension associated with Interstitial Lung Disease Overview

Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a serious Group 3 pulmonary hypertension phenotype in which pulmonary vascular dysfunction develops alongside progressive parenchymal lung disease, increasing right-ventricular load and worsening exercise capacity and prognosis. Management begins with optimization of the underlying lung disease and supportive care, while some systemic pulmonary vasodilators have raised concerns about worsening ventilation-perfusion mismatch or oxygenation. A major therapeutic advance came with inhaled treprostinil, which improved 6-minute walk distance and reduced clinical worsening in the INCREASE trial and is FDA-approved for PH-ILD. Nevertheless, current therapy primarily addresses the pulmonary vascular component and does not reliably halt or reverse the underlying interstitial lung disease. This gap is driving next-generation development, including once-daily treprostinil palmitil inhalation powder, now in Phase 3 PH-ILD development, and oral investigational therapies such as NS-863 in Phase 2. For stakeholders, PH-ILD represents an important cross-disciplinary opportunity where future value will depend on improving pulmonary vascular function while meaningfully influencing the underlying lung disease and treatment burden.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more...